Skip to content
Finance Investment

Parker Blackwood Advisers Reports Australian Economy Showing Signs of Recovery

PBA Corporation Pty Ltd 3 mins read

Parker Blackwood Advisers analysts highlight Australia’s modest economic recovery, with GDP expected to rise but still lagging historical trends. Key risks include weak capital expenditure, sluggish productivity, and uncertainty around future RBA policy moves.

PERTH, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- Parker Blackwood Advisers, a leading financial services provider has commented on the latest Australian economic trajectory that will be under the spotlight this week as fresh data is set to provide a critical assessment of the nation’s growth prospects. The December quarter national accounts, due for release by the Australian Bureau of Statistics (ABS) on Wednesday, are expected to confirm a modest acceleration in economic activity following a period of subdued expansion.

Consensus forecasts indicate that the economy likely expanded by 0.5% in the December quarter, up from 0.3% in the prior three-month period. If realized, this would translate to an annual GDP growth rate of 1.2% for 2024—a marked improvement from the 0.8% recorded in the September quarter but still well below the long-term historical average of over 3%.

"Productivity constraints and subdued private sector investment continue to weigh on economic momentum," said Nathan Jones, Chief Investment Officer at Parker Blackwood Advisers. "While fiscal policy and household spending provide some stability, sustained growth requires stronger business investment and improvements in labour productivity—key factors the RBA will be closely monitoring in its policy deliberations."

Investors will also scrutinize the Reserve Bank of Australia’s (RBA) February meeting minutes, scheduled for release on Tuesday. The central bank's decision to cut interest rates for the first time in over four years signaled a shift in monetary policy, and market participants will be seeking further clarity on the likelihood of additional easing measures in the coming months.

Beyond GDP and monetary policy, Parker Blackwood Advisers note that key data releases will shed light on Australia’s property market and government finances. CoreLogic’s monthly Home Value Index, due on Monday, will reveal whether the recent housing downturn persisted into February, while building approvals data on Thursday will gauge progress toward the federal government’s ambitious 1.2 million-home construction target over five years.

Additionally, retail trade figures on Tuesday, international trade data on Thursday, and household spending indicators on Friday will offer a broader view of consumer activity and economic strength. The government’s fiscal position will also be under scrutiny, with the market anticipating a current account deficit of $13.4 billion when balance of payments data is released.

With a pivotal week ahead for economic data and central bank insights, investors and policymakers alike will be closely watching for signals on Australia’s growth trajectory and policy outlook in 2024.

About Parker Blackwood Advisers
Founded in 2013, Parker Blackwood Advisers is a premier financial services provider based in Perth, Australia. With a focus on personalised investment strategies, the firm offers a broad range of wealth management solutions, including asset allocation, investment management, and financial planning. Managing over $4.7 billion in assets, Parker Blackwood Advisers is dedicated to helping clients achieve their financial goals through tailored, expert guidance.

Disclaimer
Parker Blackwood Advisers is a trading name of PBA Corporation Pty Ltd (ABN: 98 162 183 244), holder of AFSL 434-071. Investing carries risks, including potential loss of capital. Information provided is general and not financial advice. Past performance is not a guarantee of future results.

Mr. Paul Allen
Head of Marketing
[email protected]
08 6275 0960
Exchange Tower,
Level 17/2 The Esplanade
Perth WA, 6000

Source: Parker Blackwood Advisers


More from this category

  • Finance Investment
  • 13/01/2026
  • 13:40
Moomoo

Focused on AI, Australian investors expect 2026 to deliver

SYDNEY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Australian investors have started the new year with an overwhelming appetite for artificial intelligence and expectations of solid returns from their increasingly global portfolios, a comprehensive new survey by stock broking firm Moomoo Australia and New Zealand reveals.The detailed survey of more than 600 Australian investors' expectations and intentions for the year complements the release of moomoo's 2026 Market Outlook today, where our local experts and global research team analyse key trends in financial markets for the year ahead.And this year, investors are committing to high-growth sectors, including AI – showing a willingness…

  • Finance Investment, Oil Mining Resources
  • 13/01/2026
  • 10:22
Jane Morgan Management

Patriot Resources reports significant silver and gold results validating Kitumba polymetallic target in Zambia

Perth, Australia – 13 January 2026: Patriot Resources Limited (ASX: PAT) has reported significant silver and gold assay results from its Phase 1 trenching program at Target B1 within the Company’s 80%-owned Kitumba 27715 Project in Zambia, further validating the prospect as a near-surface polymetallic system. The latest results add silver and gold credits to previously announced strong copper, zinc and lead geochemistry, reinforcing the scale and potential economic significance of the mineralised system. The Company said the combination of metals highlights a unique polymetallic signature and strengthens confidence in Target B1 as a priority focus for ongoing exploration. Notable…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.